Chemomab Therapeutics Ltd. (CMMB)
 NASDAQ: CMMB · Real-Time Price · USD
 2.980
 -0.110 (-3.56%)
  At close: Oct 30, 2025, 4:00 PM EDT
2.980
 0.00 (0.01%)
  After-hours: Oct 30, 2025, 7:57 PM EDT
Chemomab Therapeutics Employees
Chemomab Therapeutics had 20 employees as of December 31, 2021.
Employees 
 20
Change 
 n/a
Growth 
 n/a
Revenue / Employee 
 n/a
Profits / Employee 
 -$591,300
Market Cap 
15.42M
Employees Chart
Employees History
| Date | Employees | Change | Growth | 
|---|---|---|---|
| Dec 31, 2021 | 20 | - | - | 
Related Stocks
| Company Name | Employees | 
|---|---|
| UnitedHealth Group | 400,000 | 
| Johnson & Johnson | 138,100 | 
| Thermo Fisher Scientific | 125,000 | 
| Abbott Laboratories | 114,000 | 
| AstraZeneca | 92,900 | 
| Novo Nordisk | 77,349 | 
| Novartis AG | 75,883 | 
| Merck & Co. | 75,000 | 
CMMB News
- 2 months ago - Chemomab Therapeutics to Present at H.C. Wainwright 27th Annual Global Investment Conference - GlobeNewsWire
- 2 months ago - Chemomab Therapeutics Announces Second Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 4 months ago - Chemomab Announces Oral Presentation of Positive Nebokitug Phase 2 Clinical Data in Primary Sclerosing Cholangitis at BSG Live'25 - GlobeNewsWire
- 5 months ago - Chemomab Reports Positive Feedback From Two Recent FDA Meetings Supporting Phase 3 Advancement of Nebokitug in Primary Sclerosing Cholangitis - GlobeNewsWire
- 5 months ago - Chemomab Announces New Patent Awards for Its First-in-Class Agent Nebokitug that is Positioned to Potentially Become the First Approved Drug for Primary Sclerosing Cholangitis - GlobeNewsWire
- 6 months ago - Chemomab Therapeutics Announces First Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 6 months ago - Chemomab Announces Presentation of Positive Nebokitug Phase 2 Clinical Data in Primary Sclerosing Cholangitis in Distinguished Plenary Session at DDW 2025 - GlobeNewsWire
- 6 months ago - Chemomab Reports New Positive Clinical Data at EASL 2025 Supporting Nebokitug's Impact in Primary Sclerosing Cholangitis and Related Diseases - GlobeNewsWire